HISUN(SH:600267) Zheng Quan Zhi Xing·2025-08-25 17:05Core Viewpoint - Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has received approval for the production of Minocycline Hydrochloride API, which is expected to enhance the company's product line and market competitiveness [1][3]. Group 1: Drug Approval Details - The Minocycline Hydrochloride API has been granted a registration number Y20240000032 and a notification number 2025YS00742 by the National Medical Products Administration [1]. - The product is packaged in 5kg bags and is approved for domestic production [1]. Group 2: Indications and Market Data - Minocycline Hydrochloride is indicated for various infections caused by sensitive pathogens, including but not limited to urinary tract infections, superficial pyogenic infections, and bacterial pneumonia [2][3]. - Global sales of Minocycline Hydrochloride API are projected to be approximately 35,648.65 kg in 2024, with domestic sales around 7,914.50 kg [3]. Group 3: Company Investment and Development - The company has invested approximately 19.21 million RMB in the research and development of this drug [3]. - The approval signifies that the product meets national technical standards for drug approval, allowing for production and sales [3].